Dr. Zhiyong Yu 于志勇
Chief Physician, Research Professor
Breast Surgery, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical oncology and diagnosis of breast cancer. Focuses on comprehensive treatment, salvage therapy for complex advanced cases, early diagnosis techniques, suspicious lesion localization biopsy, and post-operative breast reconstruction.
Dr. Yu holds a PhD and completed postdoctoral training at Fudan University, Oregon Health & Science University, and Wayne State University/Karmanos Cancer Center. Holds US surgical oncology certification. Professor at Shandong University and Director of Breast Department I. Research focuses on triple-negative breast cancer resistance and metastasis models. Authored three books and over 30 SCI papers.
Professional roles
- Vice Chair, Breast and Thyroid Professional Committee, Shandong Medical Doctor Association
- Standing Committee Member, Breast Disease Professional Committee, China Medicine Education Association
- Standing Committee Member, Breast Disease Branch, International Exchange and Promotion Association of Healthcare
- Member, Breast Group, Chinese Association of Plastics and Aesthetics
Name order: in Chinese the family name comes first (Yu Zhiyong). Papers usually list the name as Zhiyong Yu or Yu Z.
Selected publications
68 papers on PubMed matched by name and affiliation; 37 as first or senior author since 2016. Most recent first- or senior-author papers:
- Plast Reconstr Surg Glob Open, 2026 (senior author): Reconstructive Management for Chest Wall Radiation-induced Ulcers Following Mastectomy. PubMed 42631255
- Curr Pharm Biotechnol, 2026 (senior author): Cyperotundone Regulates Polo-like Kinase 1-mediated Glycolysis to Inhibit the Proliferation of Breast Cancer Cells. PubMed 42337879
- Breast Cancer (Dove Med Press), 2026 (senior author): The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer. PubMed 42199240
- Front Oncol, 2026 (senior author): A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib. PubMed 41858362
- Front Pharmacol, 2026 (senior author): Induction of immunogenic cell death by active components of natural products reshaping the tumor microenvironment for enhanced antitumor immunity. PubMed 41675981
- Breast Cancer (Dove Med Press), 2026 (senior author): Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer. PubMed 41868694
- Breast Cancer (Dove Med Press), 2025 (senior author): Clinical Prognosis and Nomograms for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy. PubMed 40735052
- Curr Pharm Biotechnol, 2025 (senior author): Ethanolic Extract of Cyperus rotundus Augments Chemosensitivity to Docetaxel and Suppresses Autophagic Flux in HER2-Positive Breast Cancer Cells. PubMed 40696560
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion